Haematologic Technologies is a pioneer in the biotechnology and manufacturing industries, boasting a rich history dating back to 1987. The company's dedicated focus on manufacturing excellence in plasma-derived coagulation proteins and research tools is encapsulated in their slogan, which emphasizes a commitment to superior quality and continuous innovation.
Their primary offerings include premium plasma-derived coagulation proteins, antibodies, factor-deficient plasmas, and blood collection tubes tailored for in vitro research applications. What sets them apart is their unwavering dedication to implementing continuous improvements in manufacturing processes and stringent quality control measures, ensuring that their products maintain a competitive edge over those of their peers.
As of now, specific details regarding their headquarter location, last investment, and the corresponding investors have not been disclosed. However, with their established reputation and focus on cutting-edge biotechnology, Haematologic Technologies presents itself as an intriguing prospect for potential investors seeking to align themselves with a leader in the production of plasma-derived coagulation proteins and related research tools.
